Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
Sign Up to like & getrecommendations! Published in 2018 at "Animal Cells and Systems"
DOI: 10.1080/19768354.2018.1512521
Abstract: ABSTRACT Here, we investigated the possible anti-cancer properties of bromelain in Kras mutant human colorectal carcinoma cell lines and a mouse model harboring a Kras mutation. Cell growth and proliferation were significantly reduced in the… read more here.
Keywords: mutant colorectal; bromelain; colorectal cancer; kras mutant ... See more keywords
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/0008-5472.can-22-0198
Abstract: This co-clinical trial of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer demonstrates therapeutic efficacy in patient-derived xenografts and safety in patients, identifies biomarkers of response, and uncovers targetable mechanisms of resistance. read more here.
Keywords: ras mutant; mek cdk4; mutant colorectal; colorectal cancer ... See more keywords
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-21-0941
Abstract: Abstract The fact that 10% of colorectal cancer tumors harbor BRAF V600E mutations suggested targeting BRAF as a potential therapy. However, BRAF inhibitors have only limited single-agent efficacy in this context. The potential for combination… read more here.
Keywords: wnt catenin; braf; mutant colorectal; braf mutant ... See more keywords
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-22-0301
Abstract: Purpose Novel covalent inhibitors of KRASG12C have shown limited response rates in KRASG12C mutant (MT) colorectal cancer (CRC) patients. Thus, novel KRASG12C inhibitor combination strategies that can achieve deep and durable responses are needed. Experimental… read more here.
Keywords: cancer; apoptosis; mutant colorectal; krasg12c ... See more keywords
Abstract 1923: KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz)
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs18-1923
Abstract: Background: KRAS-mt CRC has constitutively activated RAF-MEK-ERK pathways and resistance to anti-EGFR therapies. In pre-clinical models, we found that cells with inflammatory subtype tumors were sensitive to the MEK-inhibitor, MEK162, plus N, regardless of KRAS… read more here.
Keywords: mutant colorectal; stem like; combination; kras mutant ... See more keywords
Frequency and Clinicopathological Characteristics of Patients With KRAS/BRAF Double-Mutant Colorectal Cancer: An In Silico Study
Sign Up to like & getrecommendations! Published in 2022 at "Pathology and Oncology Research"
DOI: 10.3389/pore.2022.1610206
Abstract: KRAS and BRAF mutations are currently thought to be mutually exclusive as their co-occurrence is extremely rare. Therefore, clinicopathological and molecular characteristics of colorectal carcinoma with KRAS/BRAF double mutations are unclear. We aimed to investigate… read more here.
Keywords: kras braf; mutant colorectal; braf double; colorectal carcinoma ... See more keywords